Innovent Biologics, Inc. (IVBXF)
OTCMKTS · Delayed Price · Currency is USD
12.03
-1.62 (-11.87%)
Sep 8, 2025, 2:50 PM EDT
Innovent Biologics Revenue
Innovent Biologics had revenue of 5.95B CNY in the half year ending June 30, 2025, with 120.36% growth. This brings the company's revenue in the last twelve months to 11.42B, up 53.18% year-over-year. In the year 2024, Innovent Biologics had annual revenue of 9.42B with 51.82% growth.
Revenue (ttm)
11.42B CNY
Revenue Growth
+53.18%
P/S Ratio
13.85
Revenue / Employee
2.02M CNY
Employees
5,659
Market Cap
22.09B USD
Revenue Chart
* This company reports financials in CNY.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 9.42B | 3.22B | 51.82% |
Dec 31, 2023 | 6.21B | 1.65B | 36.21% |
Dec 31, 2022 | 4.56B | 286.65M | 6.71% |
Dec 31, 2021 | 4.27B | 425.91M | 11.08% |
Dec 31, 2020 | 3.84B | 2.80B | 266.94% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Veradigm | 588.02M |
Elite Pharmaceuticals | 105.45M |
Tian'an Technology Group | 2.12M |
Glass House Brands | 221.55M |
HealthLynked | 2.58M |
Northwest Biotherapeutics | 1.09M |
American Oncology Network | 1.76B |
Silence Therapeutics | 27.17M |
Innovent Biologics News
- 12 days ago - Innovent Biologics estimates ~50% jump in 2025 revenue - Seeking Alpha
- 12 days ago - Innovent Biologics reports interim results - Seeking Alpha
- 12 days ago - Innovent Announces 2025 Interim Results and Business Updates - PRNewsWire
- 15 days ago - Innovent Biologics Announces U.S. FDA IND Approval for the First Global MRCT Phase 3 Study ... - GuruFocus
- 15 days ago - Innovent Biologics Announces U.S. FDA IND Approval for the First Global MRCT Phase 3 Study (MarsLight-11) of IBI363 (PD-1/IL-2α-bias) in Squamous Non-Small Cell Lung Cancer - PRNewsWire
- 5 weeks ago - Innovent Receives U.S. FDA Approval for IND Application of Oral GLP-1R Agonist IBI3032 - PRNewsWire
- 7 weeks ago - Nature Medicine Published Phase 1 Results of Innovent Biologics' Anti-CLDN18.2 ADC (IBI343) in Patients with Advanced Gastric/Gastroesophageal Junction Adenocarcinoma - PRNewsWire
- 7 weeks ago - ‘China’s Ozempic’ pioneer inks deal with JD Health for online distribution - South China Morning Post